Open AccessEffect of Add-On Therapy of Sodium-Glucose Cotransporter 2 Inhibitors and Dipeptidyl Peptidase 4 Inhibitors on Adipokines in Type 2 Diabetes Mellitus
Author(s) -
Abid Shaheer,
Ashok Kumar,
P.B. Me,
Mahir Jallo,
Shaikh Altaf Basha
Publication year - 2021
Publication title -
journal of clinical medicine research
Language(s) - English
Resource type - Journals
eISSN - 1918-3011
pISSN - 1918-3003
DOI - 10.14740/jocmr4510
Subject(s) - medicine , metformin , adipokine , endocrinology , adiponectin , type 2 diabetes , type 2 diabetes mellitus , diabetes mellitus , postprandial , dipeptidyl peptidase 4 , lipid profile , retinol binding protein 4 , pharmacology , insulin resistance
Excess adiposity is associated with an increased risk of cardiovascular disease due to metabolic changes in the body. Visceral obesity increases the risk of diabetes mellitus through adipocytokines and hence the effective targeting therapies are essential to control obesity in high-risk individuals. The study's main objective was to evaluate the effect of add-on therapy of sodium-glucose cotransporter 2 (SGLT2) inhibitors and dipeptidyl peptidase 4 (DPP4) inhibitors on visceral fat-associated serum adipokines.